Structure Therapeutics (NASDAQ:GPCR) Announces Earnings Results

Structure Therapeutics (NASDAQ:GPCR) posted its quarterly earnings data on Thursday. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01, Zacks reports.

Structure Therapeutics Trading Up 4.1 %

Shares of Structure Therapeutics stock opened at $23.75 on Friday. The company has a market cap of $1.36 billion, a P/E ratio of -32.09 and a beta of -2.75. Structure Therapeutics has a 1 year low of $19.61 and a 1 year high of $62.74. The stock has a 50-day moving average price of $26.58 and a 200 day moving average price of $33.59.

Wall Street Analyst Weigh In

Several analysts recently commented on GPCR shares. HC Wainwright restated a “buy” rating and set a $80.00 target price on shares of Structure Therapeutics in a report on Thursday, December 19th. William Blair initiated coverage on Structure Therapeutics in a research note on Friday. They set an “outperform” rating for the company. JMP Securities reaffirmed a “market outperform” rating and set a $91.00 target price on shares of Structure Therapeutics in a report on Wednesday, December 18th. Finally, Stifel Nicolaus began coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They issued a “buy” rating and a $50.00 price target for the company. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $81.29.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.